Seroprevalence and risk factors associated with HTLV-I/II infection in injection drug users in northern New Jersey. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Seroprevalence and risk factors associated with HTLV-I/II infection in injection drug users in northern New Jersey.

J Addict Dis. 1995;14(3):51-66. Unique Identifier : AIDSLINE MED/96127013
Freeman RC; Rodriguez GM; French JF; New Jersey State Department of Health, Division of Alcoholism,; Drug Abuse, and Addiction Services, Newark, USA.

Abstract: Data from an AIDS Demonstration Research project in Paterson, NJ, that enrolled out-of-treatment injection drug users (IDUs) were analyzed to detect demographic patterns and risk factors associated with infection with human immunodeficiency virus (HIV) and human T-lymphotropic virus types I or II (HTLV-I/II). Of 410 IDUs screened, 44.2% were HIV-positive and 19.3% were HTLV-I/II-positive. African-Americans were significantly more likely than other racial groups to be HTLV-I/II-seropositive and to be HIV-seropositive. Over one-fifth of African-Americans--but no Latinos or whites--were doubly infected with HIV and HTLV-I/II. In logistic regression analysis, African-American race, long-term injection drug use, and age were significant predictors of HTLV-I/II-seropositivity. While the associations between recent needle practices and HTLV-I/II-seropositivity fell short of significance, the trends in the data were consistent with a hypothesis that HTLV-I/II is transmitted through the sharing of injection equipment. Public health implications of the data are discussed.
Keywords: Adolescence Adult Aged Comparative Study Human HTLV-BLV Infections/BLOOD/*COMPLICATIONS/VIROLOGY HTLV-I/*ISOLATION & PURIF HTLV-II/*ISOLATION & PURIF Middle Age Racial Stocks Sex Factors Substance Abuse, Intravenous/*COMPLICATIONS Support, U.S. Gov't, P.H.S. JOURNAL ARTICLEKWDadolescenceadultagedcomparativestudyhumanhtlv-blvinfections/blood/KWDcomplications/virologyhtlv-i/KWDisolation&purifhtlv-ii/KWDisolation&purifmiddleageracialstockssexfactorssubstanceabuse,intravenous/KWDcomplicationssupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticle
960530
M9651067

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .